MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-026-73300-z

Медицинская библиотека · Nature communications · 2026

Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis.

Nomura Teiko Komori, Heishima Kazuki, Mukai Hidefumi, Arai Kosuke, Elhelaly Abdelazim Elsayed, Fuchigami Hirobumi, Warashina Shota, Tahara Tsuyoshi, Hyodo Fuminori, Matsuo Masayuki, Yasunaga Masahiro, Aoki Kazunori, Honda Ryo

СтатьяПеревод пока не подготовлен

Аннотация

Mutations in K/H/N-RAS occur in approximately 30% of human cancers, yet most RAS mutants remain undruggable in clinical settings. Here, we describe a protein-based pan-RAS inhibitor, RRSP-RBD, that combines a RAS/Rap1A-specific endopeptidase (RRSP) with a RAS-binding domain (RBD). This engineered fusion protein localizes to RAS on the plasma membrane, where it cleaves RAS, disrupts RAS-effector interactions, and effectively inhibits downstream RAS signaling. To achieve intracellular delivery of RRSP-RBD in vivo, we engineer two cell-permeable variants. The diphtheria toxin-based version (RRSP-RBD-DTB) demonstrates femtomolar anti-tumor potency and induces tumor regression in a xenograft mouse model. The cell-permeable peptide-based version (RRSP-RBD-TAT) exhibits robust anti-tumor activity in syngeneic models without inducing irreversible toxicity in normal tissues. Interestingly, anti-tumor efficacy of RRSP-RBD-TAT critically depends on the tumor microenvironment, requiring infiltration by IFNγ+ CD8+ T cells to mediate tumor regression. Pharmacokinetic and toxicity evaluations indicate that RRSP-RBD is tolerated under the conditions tested and support further investigation as a protein-based pan-RAS inhibitor (all mouse studies were performed in female mice).

Для цитирования: Nomura Teiko Komori, Heishima Kazuki, Mukai Hidefumi, Arai Kosuke, Elhelaly Abdelazim Elsayed, Fuchigami Hirobumi, Warashina Shota, Tahara Tsuyoshi, Hyodo Fuminori, Matsuo Masayuki, Yasunaga Masahiro, Aoki Kazunori, Honda Ryo. Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis.. Nature communications. 2026. DOI: 10.1038/s41467-026-73300-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.